Vasculitis Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

Market Overview:

The vasculitis market reached a value of USD 104.7 Million across the top 7 markets (US, EU4, UK, and Japan) in 2025. Looking forward, IMARC Group expects the top 7 major markets to reach USD 147.6 Million by 2036, exhibiting a growth rate (CAGR) of 3.07% during 2026-2036.

The vasculitis market has been comprehensively analyzed in IMARC's new report titled "Vasculitis Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036". Vasculitis refers to a rare group of diseases that result in the inflammation of blood vessels. This swelling may cause the walls of blood vessels to thicken, reducing the width of the pathway through the vessel and leading to organ and tissue damage. The most common symptoms of the illness include fever, headache, fatigue, weight loss, etc. Individuals suffering from vasculitis may also experience ulcers, blood in the stools, double vision, numbness or weakness in the foot or hand, red spots, lumps or open sores on the skin, shortness of breath, abrupt hearing loss, dizziness, etc. The diagnosis of the ailment relies on the patient's medical history, underlying symptoms, and a complete physical exam. The healthcare provider may perform various diagnostic tests and procedures, such as blood workups, X-rays, ultrasounds, computerized tomography scans, magnetic resonance imaging, anti-neutrophil cytoplasmic antibody (ANCA) test, etc., to confirm a diagnosis. Additionally, a biopsy of the affected area is recommended to assess the tissues and rule out other possible health conditions.

The rising cases of immune-mediated diseases, including rheumatoid arthritis and scleroderma, which cause the body's defense system to attack blood vessels, are primarily driving the vasculitis market. In addition to this, the increasing incidences of various risk factors, such as smoking tobacco, cocaine use, family history, certain infections, etc., are also bolstering the market growth. Moreover, the widespread adoption of potent steroids and cytotoxic drugs to reduce inflammation and provide symptom relief in patients is acting as another significant growth-inducing factor. Besides this, the inflating demand for vascular bypass surgery, which helps redirect the blood flow around the damaged vessel, thereby enhancing the overall survival rate, is also creating a positive outlook for the market. Additionally, several key players are investing in R&D activities to launch anti-inflammatory treatment alternatives with fewer side effects and toxicities. This, in turn, is augmenting the market growth. Furthermore, the emerging popularity of radiotracers that can detect macrophage activation, along with immune checkpoint activity, and provide a precise image of vascular inflammation to enable more targeted patient management, is expected to drive the vasculitis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Vasculitis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Vasculitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Vasculitis market in any manner.

Time Period of the Study

• Base Year: 2025
• Historical Period: 2020-2025
• Market Forecast: 2026-2036

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the vasculitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the vasculitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current vasculitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Vasculitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2025 and how are they expected to perform till 2036?
• What was the country-wise size of the Vasculitis across the seven major markets in 2025 and what will it look like in 2036?
• What is the growth rate of the Vasculitis across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2020-2036) of Vasculitis across the seven major markets?
• What is the number of prevalent cases (2020-2036) of Vasculitis by age across the seven major markets?
• What is the number of prevalent cases (2020-2036) of Vasculitis by gender across the seven major markets?
• What is the number of prevalent cases (2020-2036) of Vasculitis by type across the seven major markets?
• How many patients are diagnosed (2020-2036) with Vasculitis across the seven major markets?
• What is the size of the Vasculitis’ patient pool (2020-2025) across the seven major markets?
• What would be the forecasted patient pool (2026-2036) across the seven major markets?
• What are the key factors driving the epidemiological trend of Vasculitis?
• What will be the growth rate of patients across the seven major markets?

Vasculitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Vasculitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Vasculitis market?
• What are the key regulatory events related to the Vasculitis market?
• What is the structure of clinical trial landscape by status related to the Vasculitis market?
• What is the structure of clinical trial landscape by phase related to the Vasculitis market?
• What is the structure of clinical trial landscape by route of administration related to the Vasculitis market?